BIOMARKERS OF VASCULAR DISEASE PROGRESSION IN TYPE 1 DIABETES MELLITUS (BVMARKERS)
Principal Investigator: Patricia A. Cleary, M.S.
The goal of this project is to elucidate the value of selected biomarkers in predicting the development of micro-and macrovascular complications in Type 1 diabetes and to determine if several risk factors, some unique to diabetes, may interact to augment vascular risk. This study measures three classes of biomarkers: i.) endothelial cell dysfunction - soluble ICAM-1, VCAM, and E selection; ii.) inflammation - interleukin - 6, CRP, and soluble TNF receptors; iii.) fibrinolytic/clotting system - fibrinogen, plasminogen activator inhibitor - 1 and tissue plasminogen activator. The study assays these biomarkers longitudinally in samples, obtained from the well characterized DCCT/EDIC cohort of type 1 diabetes, at the DCCT baseline and closeout phases, and in years 3-5 and 9-12 of the EDIC phase of the study. Funded by NIDDK (R01DK081352) through a subagreement with the Medical University of South Carolina, 2008-2012.)